Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 11, 2021LeukemiaOpen Access

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJerald P. RadichAHAndreas HochhausTMTamás Masszi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Radich et al. (2021) studied this question.

synapsesocial.com/papers/6a6e6424f44fa9f079dc2670https://doi.org/10.1038/s41375-021-01205-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population2016 · 906 citations
  2. 2Chronic myeloid leukemia in the Netherlands: a population‐based study on incidence, treatment, and survival in 3585 patients from 1989 to 20122015 · 42 citations
  3. 3Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants2017 · 342 citations
  4. 4European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia2020 · 1,549 citations
  5. 5Epidemiologic Signatures in Cancer2019 · 208 citations